PBYI - Puma Biotechnology, Inc.
| Previous Close | 9.29 |
| Open | 9.46 |
| Bid | 9.24 x 800 |
| Ask | 9.43 x 1100 |
| Day's Range | 9.22 - 9.78 |
| 52 Week Range | 6.26 - 43.90 |
| Volume | 1893474 |
| Avg. Volume | 1,740,119 |
| Market Cap | 365M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.47 |
| Earnings Date | Feb 26, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.13 |
- Business Wire
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Puma Biotechnology presented interim results of its CONTROL Trial on Dec. 13 at the 2019 San Antonio Breast Cancer Symposium.
- GuruFocus.com
Seattle Genetics' Cancer Study Boosts Prospects, Takeover Appeal
Needham analyst raises target price after promising results of drug trial Continue reading...
- Business Wire
plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer
Puma announced its collaborators at The Institute of Cancer Research presented results from the plasmaMATCH Trial in patients treated with neratinib
- Benzinga
The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
- Business Wire
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
Puma Biotechnology presented results from its ongoing SUMMIT "basket" trial in a poster at the 2019 San Antonio Breast Cancer Symposium.
- Insider Monkey
Do Hedge Funds Love Puma Biotechnology Inc (PBYI)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Zacks
Why Is Puma Biotech (PBYI) Down 1% Since Last Earnings Report?
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Those Who Purchased Puma Biotechnology (NASDAQ:PBYI) Shares Five Years Ago Have A 96% Loss To Show For It
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
- Zacks
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma Biotech (PBYI) stretches its license deal with Pierre Fabre, granting the latter commercial rights to Nerlynx in new countries across Europe and parts of Africa. Stock rallies.
- Benzinga
The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
- Business Wire
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia has received marketing approval of NERLYNX® in Singapore from the Health Sciences Authority , a statutory board under the Ministry of Health of the Singapore Government.
- Business Wire
CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries
Last name of Chief Executive Officer of Pierre Fabre Pharmaceuticals in fourth paragraph should read: Lowinski .
- Zacks
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents
Edited Transcript of PBYI earnings conference call or presentation 6-Nov-19 9:30pm GMT
Q3 2019 Puma Biotechnology Inc Earnings Call
- Zacks
Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down
Puma Biotech (PBYI) incurs narrower loss in Q3. Sales of Nerlynx decline sequentially. Stock drops 18%.
- Zacks
Puma Biotech (PBYI) Reports Q3 Loss, Lags Revenue Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of 42.11% and -7.43%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Puma Biotechnology Reports Third Quarter 2019 Financial Results
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for the third quarter 2019 compared to the third quarter 2018.
- Benzinga
The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 5.) Agile Therapeutics Inc (NASDAQ: AGRX ) (follow-on ...
- Business Wire
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Puma Biotechnology, Inc. announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in Hong Kong to market NERLYNX® for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who have completed adjuvant trastuzumab-based therapy ...
- Business Wire
Puma Biotechnology to Present at the Credit Suisse Healthcare Conference
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:55 a.m.
- Insider Monkey
Here is What Hedge Funds Think About Puma Biotechnology Inc (PBYI)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
- Zacks
Earnings Preview: Puma Biotech (PBYI) Q3 Earnings Expected to Decline
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Wednesday, November 6, 2019 following release of its third quarter 2019 financial results. Please dial in at least ten minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.
- Simply Wall St.
How Much Did Puma Biotechnology, Inc.'s (NASDAQ:PBYI) CEO Pocket Last Year?
Alan Auerbach became the CEO of Puma Biotechnology, Inc. (NASDAQ:PBYI) in 2011. First, this article will compare CEO...
- Benzinga
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Belying the popular notion that oncology biotechs are lucrative investment options,Goldman Sachs is taking a bearish stance on Puma Biotechnology Inc (NASDAQ: PBYI ) and Clovis Oncology Inc (NASDAQ: CLVS ...
